Cargando…

Human in-vivo 31P MR Spectroscopy of Benign and Malignant Breast Tumors

OBJECTIVE: To assess the potential clinical utility of in-vivo 31P magnetic resonance spectroscopy (MRS) in patients with various malignant and benign breast lesions. MATERIALS AND METHODS: Seventeen patients with untreated primary malignant breast lesions (group I), eight patients with untreated be...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jeong Mi, Park, Jae Hyung
Formato: Texto
Lenguaje:English
Publicado: The Korean Radiological Society 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2718106/
https://www.ncbi.nlm.nih.gov/pubmed/11752975
http://dx.doi.org/10.3348/kjr.2001.2.2.80
_version_ 1782169965342752768
author Park, Jeong Mi
Park, Jae Hyung
author_facet Park, Jeong Mi
Park, Jae Hyung
author_sort Park, Jeong Mi
collection PubMed
description OBJECTIVE: To assess the potential clinical utility of in-vivo 31P magnetic resonance spectroscopy (MRS) in patients with various malignant and benign breast lesions. MATERIALS AND METHODS: Seventeen patients with untreated primary malignant breast lesions (group I), eight patients with untreated benign breast lesions (group II) and seven normal breasts (group III) were included in this study. In-vivo 31P MRS was performed using a 1.5 Tesla MR scanner. Because of the characteristics of the coil, the volume of the tumor had to exceed 12 cc (3×2×2 cm), with a superoinferior diameter at least 3 cm. Mean and standard deviations of each metabolite were calculated and metabolite ratios, such as PME/PCr, PDE/PCr, T-ATP/PCr and PCr/T-ATP were calculated and statistically analyzed. RESULTS: Significant differences in PME were noted between groups I and III (p=0.0213), and between groups II and III (p=0.0213). The metabolite ratios which showed significant differences were PME/PCr (between groups II and III) (p=0.0201), PDE/PCr (between groups I and III, and between groups II and III) (p=0.0172), T-ATP/PCr (between groups II and III) (p=0.0287), and PCr/T-ATP (between groups II and III) (p=0.0287). There were no significant parameters between groups I and II. CONCLUSION: In-vivo 31P MRS is not helpful for establishing a differential diagnosis between benign and malignant breast lesions, at least with relatively large lesions greater than 3 cm in one or more dimensions.
format Text
id pubmed-2718106
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher The Korean Radiological Society
record_format MEDLINE/PubMed
spelling pubmed-27181062009-07-30 Human in-vivo 31P MR Spectroscopy of Benign and Malignant Breast Tumors Park, Jeong Mi Park, Jae Hyung Korean J Radiol Original Article OBJECTIVE: To assess the potential clinical utility of in-vivo 31P magnetic resonance spectroscopy (MRS) in patients with various malignant and benign breast lesions. MATERIALS AND METHODS: Seventeen patients with untreated primary malignant breast lesions (group I), eight patients with untreated benign breast lesions (group II) and seven normal breasts (group III) were included in this study. In-vivo 31P MRS was performed using a 1.5 Tesla MR scanner. Because of the characteristics of the coil, the volume of the tumor had to exceed 12 cc (3×2×2 cm), with a superoinferior diameter at least 3 cm. Mean and standard deviations of each metabolite were calculated and metabolite ratios, such as PME/PCr, PDE/PCr, T-ATP/PCr and PCr/T-ATP were calculated and statistically analyzed. RESULTS: Significant differences in PME were noted between groups I and III (p=0.0213), and between groups II and III (p=0.0213). The metabolite ratios which showed significant differences were PME/PCr (between groups II and III) (p=0.0201), PDE/PCr (between groups I and III, and between groups II and III) (p=0.0172), T-ATP/PCr (between groups II and III) (p=0.0287), and PCr/T-ATP (between groups II and III) (p=0.0287). There were no significant parameters between groups I and II. CONCLUSION: In-vivo 31P MRS is not helpful for establishing a differential diagnosis between benign and malignant breast lesions, at least with relatively large lesions greater than 3 cm in one or more dimensions. The Korean Radiological Society 2001 2001-06-30 /pmc/articles/PMC2718106/ /pubmed/11752975 http://dx.doi.org/10.3348/kjr.2001.2.2.80 Text en Copyright © 2001 The Korean Radiological Society http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Park, Jeong Mi
Park, Jae Hyung
Human in-vivo 31P MR Spectroscopy of Benign and Malignant Breast Tumors
title Human in-vivo 31P MR Spectroscopy of Benign and Malignant Breast Tumors
title_full Human in-vivo 31P MR Spectroscopy of Benign and Malignant Breast Tumors
title_fullStr Human in-vivo 31P MR Spectroscopy of Benign and Malignant Breast Tumors
title_full_unstemmed Human in-vivo 31P MR Spectroscopy of Benign and Malignant Breast Tumors
title_short Human in-vivo 31P MR Spectroscopy of Benign and Malignant Breast Tumors
title_sort human in-vivo 31p mr spectroscopy of benign and malignant breast tumors
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2718106/
https://www.ncbi.nlm.nih.gov/pubmed/11752975
http://dx.doi.org/10.3348/kjr.2001.2.2.80
work_keys_str_mv AT parkjeongmi humaninvivo31pmrspectroscopyofbenignandmalignantbreasttumors
AT parkjaehyung humaninvivo31pmrspectroscopyofbenignandmalignantbreasttumors